Liver Transplant Rejection Pipeline Landscape with Therapeutic Assessment Reviewed in H2 2017

Report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.


Albany, NY -- (SBWire) -- 10/04/2017 --Rejection is a normal reaction of the body to a foreign object. When a new liver is placed in a person's body, the body sees the transplanted organ as a threat and tries to attack it. Recently, a number of studies have investigated the impact of liver transplantation along with its rejection in a detailed study titled as "Liver Transplant Rejection - Pipeline Review, H2 2017". Market Research Hub (MRH) has broadcasted this latest study to its vast repository, which offers comprehensive information on the therapeutic under development for liver transplant rejection and overall pipeline landscape. The pipeline products defined in this report have been analyzed on the basis of their development stage, from pre-registration to discovery.

Request Free Sample Report :

It has been analyzed that Organ transplantation is slowly emerging as an effective method for the treatment of end-stage organ failure. Due to the increasing incidence of chronic diseases, the demand for organ replacement has increased considerably across the world. This subsequently fuels demand for advanced immunosuppressant drugs to prevent organ rejection post-transplantation. The first section of the report presents an overview of Liver transplant rejection. This section highlights the development of therapeutics, pipeline products utilized in liver transplant rejection and a comparative analysis of these pipeline products.

Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or grow, unlike any other organ in the body. In general, the liver is a highly resistant organ that can actually repair itself, although in certain progressed cases of liver damage, a liver transplant is the only option. Usually, the damaged liver is removed from the patient, the liver being replaced with a healthy donor liver. Patients may hence develop complications and ultimately reject the new organ. After the transplant, however, the liver will be rejected by the body unless immunosuppressive drugs are taken to check the body's immune system from attacking what it perceives as a dangerous foreign object.

Moreover, the analysts have conducted an assessment of therapeutics on the basis of molecule type, target, route of administration, and mechanism of action. Also, the therapeutics still under development by both universities and companies, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases have been presented. Some of the drugs profiles in the study are FX-06, MDR-202, Cellular Immunotherapy for Liver Transplantation and Rejection, ABC-294640, reparixin, TR-002, tacrolimus, Triplex and others.

Browse Full Report with TOC-

For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends and their efforts to discover new therapeutics for liver transplant rejection. At present, key players involved in the therapeutic development are Astellas Pharma Inc., Dompe Farmaceutici SpA, Biogen Inc., RedHill Biopharma Ltd., and Conatus Pharmaceuticals Inc.

Enquire about this Report-

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: 800-998-4852 (US-Canada)
Read Industry News at -

Media Relations Contact

Mark Hub
Market Research HUB

View this press release online at: